A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients.
Date
2009-04Journal
Diabetic medicine : a journal of the British Diabetic AssociationType
Research Support, N.I.H., ExtramuralResearch Support, Non-U.S. Gov't
Publisher
WileyDOI
10.1111/j.1464-5491.2009.02690.xRights
Archived with thanks to Diabetic medicine : a journal of the British Diabetic AssociationMetadata
Show full item recordAbstract
Hepatocyte nuclear factor-1 alpha (HNF1A) gene mutations are the commonest cause of monogenic diabetes, but patients are often misdiagnosed as having Type 1 diabetes and started on insulin treatment. Patients with HNF1A diabetes are particularly sensitive to the glucose-lowering effect of sulphonylureas, which are the pharmacological treatment of choice. We aimed to assess if patients do change from insulin to sulphonylurea treatment when HNF1A diabetes is confirmed and the impact of this treatment change on long-term glycaemic control.